argenex (NASDAQ:ARGX) Given New $925.00 Price Target at JPMorgan Chase & Co.

argenex (NASDAQ:ARGX) had its target price lifted by JPMorgan Chase & Co. from $830.00 to $925.00 in a research report released on Friday morning,Benzinga reports. They currently have an overweight rating on the stock.

A number of other equities research analysts have also weighed in on the company. Wells Fargo & Company lifted their price objective on argenex from $741.00 to $756.00 and gave the stock an “overweight” rating in a research report on Thursday, July 31st. Piper Sandler boosted their price objective on shares of argenex from $820.00 to $930.00 and gave the company an “overweight” rating in a research report on Tuesday. TD Cowen raised their target price on shares of argenex from $800.00 to $1,146.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Morgan Stanley raised their price objective on shares of argenex from $766.00 to $1,040.00 and gave the stock an “overweight” rating in a report on Wednesday, October 1st. Finally, Truist Financial upped their target price on argenex from $700.00 to $918.00 and gave the stock a “buy” rating in a report on Monday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $869.68.

argenex Stock Performance

Shares of NASDAQ ARGX traded up $3.63 during mid-day trading on Friday, hitting $854.65. The stock had a trading volume of 282,611 shares, compared to its average volume of 375,124. The business has a 50 day moving average price of $782.86 and a two-hundred day moving average price of $662.47. argenex has a 1 year low of $510.05 and a 1 year high of $857.48. The firm has a market cap of $52.62 billion, a P/E ratio of 36.70, a price-to-earnings-growth ratio of 0.88 and a beta of 0.45.

argenex (NASDAQ:ARGX) last posted its earnings results on Thursday, October 30th. The company reported $4.40 earnings per share for the quarter, topping analysts’ consensus estimates of $4.37 by $0.03. argenex had a net margin of 41.58% and a return on equity of 29.78%. The company had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.07 billion. Equities research analysts predict that argenex will post 3.13 EPS for the current fiscal year.

Institutional Investors Weigh In On argenex

Hedge funds have recently added to or reduced their stakes in the stock. WPG Advisers LLC bought a new position in shares of argenex during the first quarter valued at $37,000. Brooklyn Investment Group grew its position in argenex by 102.7% during the 1st quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock valued at $44,000 after purchasing an additional 38 shares during the last quarter. Bessemer Group Inc. raised its holdings in argenex by 276.5% in the third quarter. Bessemer Group Inc. now owns 64 shares of the company’s stock worth $47,000 after buying an additional 47 shares during the last quarter. MAI Capital Management raised its holdings in argenex by 866.7% in the second quarter. MAI Capital Management now owns 87 shares of the company’s stock worth $48,000 after buying an additional 78 shares during the last quarter. Finally, Mather Group LLC. bought a new position in shares of argenex in the third quarter worth approximately $50,000. 60.32% of the stock is owned by institutional investors.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.